Over the past decade, artificial intelligence (AI) and automation have reshaped clinical research. From identifying drug ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Why future-ready pharma companies must embrace AI-driven, real-time decision-making. Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how AI is stepping in to fill staffing gaps in ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how staffing reductions caused by clinical trial ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...